A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.
Inclusion Criteria:
Exclusion Criteria:
Stanford, California 94305, United States
Indianapolis, Indiana 46237, United States
Salinas, Kansas 67401, United States
Brownstown, Michigan 48183, United States
Campinas/ SP, 6198, Brazil
Shanghai, P.R. China 200025, China
Bogota, Cundinamarca, Colombia
München, 81675, Germany
Shatin N.T., HONG KONG, Hong Kong
Komae-shi, Tokyo 2018601, Japan
Katowice, 40-032, Poland
Moscow, 125167, Russia
Yaroslavl, 150062, Russia
Seoul, 137-701, South Korea
Taipei TOC, 100, Taiwan
Bangkoknoi, Bangkok 10700, Thailand
Dnipropetrovsk, 49102, Ukraine
Donetsk, 83045, Ukraine
Kyiv, 03115, Ukraine
Kyiv, 03115, Ukraine